Fig. 2From: Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspectivea, b Survival curves for paediatric patients who have not been treated with dexrazoxane who a have CHF, by age at diagnosis, and b are cancer survivors, conditional on surviving until the age at cancer diagnosis, compared to survival among the general populationBack to article page